Olivier Uwishema

Olivier Uwishema

Auto-generated profile, based on publicly available information

Olivier Uwishema

Department of Research and Education, Oli Health Magazine Organization, Kigali, Rwanda

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
CCCeline Chaaya
Celine Chaaya
VTVimala Devi Thambi
Vimala Devi Thambi
ÖSÖzge Sabuncu
Özge Sabuncu
RAReem Abedi
Reem Abedi
AOAwab Osman Ahmed Osman
Awab Osman Ahmed Osman
Helen OnyeakaHelen Onyeaka
Helen Onyeaka
The Russia-Ukraine crisis has been at the center of international talks since early 2022. This conflict, bursting after the sanitary crisis of the covid 19 pandemic, creates an atmosphere of uncertainty and instability, which negatively impacts many aspects, including mental health. Young Ukrainians have been suffering from socio-political instability for decades, and the current war, together with the Covid 19 pandemic, shatters hopes of brighter days. This commentary covers the challenges facing the younger generation in Ukraine and the impact of this situation on their mental health.

25 July 2022 in Brain and Behavior
Verified
Journal Article
Open access
OUOlivier Uwishema
Olivier Uwishema
AMAshraf Mahmoud
Ashraf Mahmoud
JSJeffrey Sun
Jeffrey Sun
ICInês F. Silva Correia
Inês F. Silva Correia
NBNiovi Bejjani
Niovi Bejjani
BDBurhan Dost
Burhan Dost
Introduction: Alzheimer's disease (AD) is a leading cause of dementia around the globe. Its pathogenesis is characterized primarily by the extracellular deposition of amyloid β peptides and intracellular neurofibrillary tangles. Despite the significant investments in neurological research, the exact molecular mechanism of AD pathogenesis is still not fully elucidated. Several studies converge on a hypothesis that pathogenic microbes might play a role in AD progression. Although this hypothesis has been considered relatively weak for decades, it has recently received considerable attention due to increasing evidence on the association between microorganisms and AD. There is a lack of experimental and scientific arguments conveying that these microorganisms engender cognitive and neuropathological deficits and modifications specific to AD, challenging the theory that it could be an infectious neurological disease. This review focuses on recent advances in the infection hypothesis and provides an overview of new findings portraying the significance of pathogenic microbes in AD and the challenges confronting the validity of the hypothesis.Methodology: Data were collected from medical journals published on PubMed, Ovid MEDLINE, ScienceDirect, and Embase bibliographical databases with a predefined search strategy. All articles considering neurological disorders, especially AD associated with infectious diseases, were included.Results: This work focused on providing an overview of new findings around the relationship between microorganisms and AD, challenges facing the validity of the theory, and recommendations on how the scientific community can best develop alternative approaches to address the pathophysiology of AD.Conclusion: While many studies reinforce the suspicion of an infectious etiology of AD, it is important to note that it is yet not validated how microorganisms’ presence in the brain can develop AD due to the limited available evidence. Certainly, ground‐breaking work is mandatory in this field of research, and these reports so far warrant a thorough investigation into how a chronic infection may remain silent while progressing its neuroinflammation. Amid this uncertainty arises the hope that many researchers will take on this challenge and join this endeavor to benefit AD patients worldwide.

6 January 2021 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
AAAbdullahi Aborode
Abdullahi Aborode
KDKenneth Bitrus David
Kenneth Bitrus David
OUOlivier Uwishema
Olivier Uwishema
LALubem Nathaniel Agbendeh
Lubem Nathaniel Agbendeh
JIJegede Oluwatoyin Imisioluwa
Jegede Oluwatoyin Imisioluwa
FFFozia Farooq
Fozia Farooq
Malaria remains a major global health burden, killing hundreds of thousands annually, especially in sub-Saharan Africa. In December 2019, a novel illness termed COVID-19, caused by SARS-CoV-2, was reported in China. This disease soon spread around the world and was declared a pandemic by the WHO on March 11, 2020. Considering that the malaria burden is high in many low-income tropical countries with little capacity to fund malaria control and eradication programs, the fight against malaria in these regions is likely to be hindered by COVID-19. Indeed, access to health care has generally been limited during the pandemic, whereas malaria interventions, such as seasonal malaria chemoprevention, and distribution of long-lasting insecticide-treated bed nets, have been suspended because of lockdowns. Likewise, the repurposing of antimalarials for the treatment of COVID-19 and a shift in focus from the production of malaria rapid diagnostic tests to COVID-19 rapid diagnostic tests are causes for concern in malaria-endemic regions. COVID-19 has disproportionately affected developed countries, threatening their capacity to aid in malaria control efforts. Here, we address impacts of the COVID-19 pandemic on the management and control of malaria in Africa.

18 January 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
SSSanobar Shariff
Sanobar Shariff
AHAlicia Kwan Su Huey
Alicia Kwan Su Huey
NSNishant Parag Soni
Nishant Parag Soni
AYAmer Yahia
Amer Yahia
DHDoha Hammoud
Doha Hammoud
MWMagda Wojtara
Magda Wojtara
Introduction: Gut microbiota has emerged as a pivotal player in cardiovascular health and disease, extending its influence beyond the gut through intricate metabolic processes and interactions with the immune system. Accumulating evidence supports a significant association between gut microbiota and cardiovascular diseases such as atherosclerosis, hypertension, and heart failure. Dietary patterns have been identified as key factors shaping the composition of the gut microbiota and exerting notable impacts on cardiovascular health. Probiotics and prebiotics have shown promise in mitigating the risks of cardiovascular disease by modulating key cardiovascular parameters. Faecal microbiota transplantation (FMT) has recently emerged as a novel and intriguing therapeutic strategy. Aim: This review paper aims to explore and elucidate the multifaceted role of gut microbiota in cardiovascular health. It will also address the prevailing challenges and limitations in gut microbiota studies, emphasizing the importance of future research in overcoming these obstacles to expand our understanding of the gut-heart axis. Materials and methods: A comprehensive literature search was conducted using various databases including ClinicalTrials, Google Scholar, PubMed, ScienceDirect, MEDLINE, and Ovid Resources. The search strategy included utilizing keywords such as “Gut microbiota,” “Randomized controlled trials (RCTs),” “Gut-heart axis,” “Dysbiosis,” “Diet,” “Probiotics,” “Prebiotics,” “Faecal Microbiota transplantation,” “cardiovascular disease,” “Meta-analyses,” and other compatible terms thereof. Only articles written in English were considered, and selection criteria included relevance to the research objectives, reasonable sample sizes, and robust methodology. In addition to the identified articles, meta-analyses, animal models and studies, and references from the selected articles were also examined to ensure a comprehensive review of the literature. Results: Dietary patterns exert a significant influence on the composition of the gut microbiota, and certain diets, such as the Mediterranean diet, have been associated with a favourable gut microbiota profile and a reduced risk of cardiovascular disease (CVD). Probiotics and prebiotics have emerged as potential interventions to mitigate CVD risks by modulating blood pressure, glycemic control, lipid profiles, and gut dysbiosis. Another innovative therapeutic approach is FMT, which involves transferring faecal material from a healthy donor to restore a balanced gut microbiota. FMT holds promise for improving cardiometabolic parameters in individuals with CVD, although further research is needed to elucidate its precise mechanisms and assess its effectiveness. Conclusion: The gut microbiota is emerging as a potential therapeutic target for CVD prevention and management. However, current research has limitations, including the need for larger and more diverse studies, the challenges of establishing causality, and concerns regarding the long-term consequences and safety of gut microbiota modulation. Despite these limitations, understanding the gut-heart axis holds promise for the development of personalized therapies and interventions for cardiovascular health. Further research is needed to expand our knowledge and address the ethical and safety issues associated with gut microbiota modification.

24 November 2021 in Tropical Medicine and Health
Verified
Journal Article
Open access
PDF file
OUOlivier Uwishema
Olivier Uwishema
MOMelody Okereke
Melody Okereke
Helen OnyeakaHelen Onyeaka
Helen Onyeaka
Mohammad Mehedi HasanMohammad Mehedi Hasan
Mohammad Mehedi Hasan
DDDeocles Donatus
Deocles Donatus
IAIrem Adanur
Irem Adanur
Every year, about 4 million cases and 143,000 deaths due to cholera are recorded globally, of which 54% were from Africa, reported in 2016. The outbreak and spread of cholera have risen exponentially particularly in Africa. Coupled with the recent emergence of the Coronavirus Pandemic (COVID-19) in Africa, the local health systems are facing a double burden of these infectious diseases due to their cumulative impact. In this paper, we evaluate the dual impact of cholera and COVID-19 in Africa and suggest plausible interventions that can be put in place to cushion its impact.

21 April 2022 in Brain and Behavior
Verified
Journal Article
Open access
OUOlivier Uwishema
Olivier Uwishema
Helen OnyeakaHelen Onyeaka
Helen Onyeaka
RBRawa Badri
Rawa Badri
AYAyşe Nazlı Yücel
Ayşe Nazlı Yücel
AKAhmet Kayhan KORKUSUZ
Ahmet Kayhan KORKUSUZ
ECElie Chalhoub
Elie Chalhoub
Introduction: Parkinson's disease is one of the progressive neurodegenerative diseases from which people suffer for years. The mechanism of this disease is associated with a decrease in the number of dopaminergic neurons in the substantia nigra (SN) while Lewy bodies are still present. As a result, both motor—ridity, tremor, and bradykinesia—and non‐motor symptoms such as anxiety and depression. Nowadays, it is well known that the cause behind Parkinson's disease is mainly environmental changes, genetic susceptibility, and toxins. Unfortunately, there is no cure for the disease but treatments. The replacement of lost neurons, α‐synuclein and apomorphine, is currently being studied for new therapies. This article focuses on history, mechanism, factors causing Parkinson's disease as well as future therapies for the cure of the diseases.Methodology: Data were collected from medical journals published on PubMed, The Lancet, Cells, and Nature Reviews Neurology databases with a predefined search strategy. All articles considering new therapies for Parkinson's disease were considered.Results: The pathophysiology of Parkinson's disease is currently reasonably understood. However, there is no definitive cure so all the treatments focus mainly on reducing or limiting the symptoms. Current treatment studies focus on genetics, replacing lost neurons, α‐synuclein and apomorphine.Conclusion: Parkinson's disease is the most common movement disorder worldwide because of the loss of dopaminergic neurons in the substantia nigra. Its symptoms include motor dysfunctions such as rigidity, tremor, and bradykinesia and non‐motor dysfunctions such as anxiety and depression. Through genetics, environmental changes and toxins analysis, it is now known that future new therapies are working on replacing lost neurons, α‐synuclein and apomorphine.